DECRISE®

GABAPENTIN

VETERINARY USE
ANXIOLYTIC DRUG FOR ORAL USE IN CATS

Formula
Each tablet of **DECRISE® 50 mg** contains:
Gabapentin ..... 50 mg
Excipients q.s.p. ……..……..100 mg

Each tablet of **DECRISE® 100 mg** contains:
Gabapentin ..... 100 mg
Excipients q.s.p. ……...200 mg

Each tablet of **DECRISE® 200 mg** contains:
Gabapentin ..... 200 mg
Excipients q.s.p. ……...400 mg

Technical Information
DECRISE® contains gabapentin, that is known to exert anxiolytic, sedative, anticonvulsant, and analgesic effects. It specifically binds to the alpha-2-delta-1 (.2_1) subunit of the presynaptic voltage-dependent calcium channels that are present in the mammalian brain, leading to a subsequent modulation of these channels. This binding inhibits the flow of calcium into nerve cells, generating a reduced release of several monoamine neurotransmitters, including norepinephrine, and decreasing the synaptic transmission of specific excitatory neurotransmitters, such as glutamate, resulting in the reduction of the fear neurotransmission circuit, that is pathologically activated by anxiety. Authors also suggest that gabapentin exerts effect on the reduced physiological release of catecholamines during the fight-and-flight response.
Absorption of gabapentin is not affected by food. Cats may present a high individual variability in the rate of oral absorption, which can occur in approximately 100 minutes after ingestion, with a bioavailability of 89%. Pharmacokinetic parameters of gabapentin after oral dosing in single and repeated doses of 20 mg/kg to healthy cats showed a mean peak plasma concentration time (T_{max}) of 1.5 hour, a mean peak plasma concentration (C_{max}) of 242 ng/ml/mg and an area under the curve (AUC) average of 1587 ng/ml/mg. Gabapentin is excreted primarily by the kidneys, so it is recommended that dose be adjusted in cats with renal disease. Studies demonstrate that gabapentin can significantly lessen stressful behaviors and aggression in cats, besides increasing the occurrence of ideal species-specific behavior, and producing attenuating effects on fear responses.

Indications
DECRISE® is an anxiolytic drug indicated for cats, to reduce stress during restraint, handling for physical examination, material collection, positioning for diagnostic tests and transport for up to 3 hours.

Dosage and how to use
DECRISE® is designed exclusively for oral route. The recommended dose is 50 to 100 mg/cat as a single dose, approximately 1 hour and 30 minutes before the stressful event or as indicated by the veterinarian.
DECRISE® showed to be effective in the reduction of stress during restraint and handling for physical examination, material collection, or positioning for diagnostic tests at single oral doses of 50 to 100 mg/cat. The 100 mg dose showed to be most potent and long-lasting and should, therefore, be considered for highly stressed animals, which require more intense sedation of up to three hours.
According to a safety study conducted in cats, **DECRISE®** showed to be safe when administered at the recommended dose and in overdose (200 mg/cat as a single dose) for 5 days.

Contraindications
DECRISE® contains gabapentin and, therefore, it is not indicated for animals with hypersensitivity to gabapentin and other components of the formula.
DECRISE® contains gabapentin and, therefore, it is not indicated for animals with severe liver disease.
DECRISE® is not indicated for pregnant or lactating females or cats under 12 months of age, since no studies have yet been carried out in these age groups.
DECRISE® is not indicated for animals with severe heart disease and/or hemodynamically unstable animals, since no studies have yet been carried out in these groups.
DECRISE® is not indicated for cats under 2.45 kg, since the safety study did not include animals under this weight.

Drug interactions
Gabapentin drug interactions are rare, but may occur with aluminum- and magnesium oxide-based antacids and cimetidine.
Antacids containing aluminum or magnesium cause a 24% reduction in the oral absorption of gabapentin. Therefore, their concurrent administration is not indicated. If the use of antacids is necessary, a two-hour interval between doses is advised.
No interactions have been observed between gabapentin and phenobarbital.

Adverse effects
The major adverse effects of gabapentin reported in cats, in decreasing order of frequency, are ataxia, lethargy, bradycardia, depression, and mydriasis. Emesis, drooling, lip-licking behavior and, less frequently, muscle fasciculation and anisocoria, have also been reported in cats given gabapentin as a single oral dose for transport and veterinary examination purposes, but with complete resolution of effects within 6 hours after dosing.
When **DECRISE®** is administered at the maximum dose recommended in the package insert (100 mg/cat as a single dose) and in overdose (200 mg/cat as a single dose), it did not alter hematological and biochemical tests, nor cause cardiovascular, respiratory and gastrointestinal changes. The animals remained healthy throughout the study period, even when used as a single daily dose for 5 consecutive days. Reactions such as prostration, lethargy, sedation and incoordination were mild, transient and did not require interventions. They occurred primarily 2 hours after treatment, when the product's peak of action occurred. Such reactions were expected, since **DECRISE®** has anxiolytic effects, reducing fear, anxiety, and stress, and facilitating the animal's safe handling.

Precautions
Because it contains gabapentin, caution should be taken when prescribing **DECRISE®** for animals with chronic renal disease; if necessary, dose adjustment is recommended.
The use in cats should be monitored according to the veterinarian's guidance.
For treatments that need to be extended beyond the period recommended in the package insert, guidance and monitoring by the Veterinarian are recommended, as well as the conduction of hematological and biochemical tests.

Poisoning and overdose
The major adverse effects expected with high doses of gabapentin in cats are sedation, lethargy, and ataxia. In case of poisoning, it is recommended to immediately seek the Veterinarian's attention for monitoring of vital signs and supportive treatment. When evaluating the acute toxicity of gabapentin in laboratory animals, effects such as ataxia, difficulty breathing, eyelid ptosis, sedation, hypoactivity or excitation have been observed. In a toxicity study conducted in mice, the only effect observed was diarrhea, with a transient and rare incidence in half of the animals given doses of 3,000 mg/kg. No deaths, nor serious injuries have been observed with gabapentin treatment.

Warnings
Veterinary products should be kept out of the reach of children and pets. They should not be stored next to food, drinks or personal hygiene products. **DECRISE®** is not indicated for pregnant or lactating females or cats under 12 months of age, as studies have not yet been conducted with these groups. Dosage adjustments should only be made under the guidance and indication of the veterinarian.

ATTENTION: THE USE BY HUMANS MAY CAUSE SERIOUS RISKS TO HEALTH.

How supplied
Paper carton containing 2 blisters with 15 bisected tablets (**DECRISE® 50 mg**).
Paper carton containing 2 blisters with 15 bisected tablets (**DECRISE® 100 mg**).
Paper carton containing 2 blisters with 15 bisected tablets (**DECRISE® 200 mg**).

Storage recommendations
Keep the product in a dry place, at room temperature (15ºC to 30ºC), away from direct sunlight and out of the reach of children and pets. In case of accidental ingestion, seek medical advice and take the product packaging with you.
The exposure of the product to extreme conditions of heat, sunlight and humidity, disrespecting the correct storage recommendations, may lead to a decrease or loss of action of the active ingredient.

Batch number, date of manufacture and expiration: See packaging.

SALE UNDER PRESCRIPTION OF THE VETERINARIAN, WITH MANDATORY RETENTION OF THE PRESCRIPTION.

Product licensed with the Ministry of Agriculture and Livestock, under no. SP 001692-6.000010 on June/9/2025.

Owned and Manufactured by

Biolab Sanus Farmacêutica Ltda.

Av. Francisco Samuel Lucchesi Filho, 1039 Bragança Paulista - SP
CEP: 12929-600

CNPJ: 49.475.833/0018-46
SAC: 0800 9415566
Technical Responsible: Daniela Ziolkowski CRF-SP 29486

Expiration date: 24 months after the manufacture date. After splitting the tablet, the remaining parts must be used within 72 hours.